Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer
Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.